Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.49 |
| ▸ | HTR2B | P41595 | 10/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 9/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417159 | 0.83 | PARP1 (0.47) | HTR2CHTR2BPARP1HTR2AMAPK1 | |
| SCHEMBL2966935 | 0.83 | PARP1 (0.47) | HTR2CHTR2BPARP1HTR2AMAPK1 | |
| Hydrochloric Acid SCHEMBL3882535 | 0.82 | PARP1 (0.46) | HTR2CHTR2BPARP1HTR2AMAPK1 | |
| SCHEMBL3591077 | 0.81 | CHRM4 (0.43) | PARP1AHRMAPT | |
| SCHEMBL3599449 | 0.80 | PARP1 (0.44) | HTR2CHTR2BPARP1HTR2AMAPK1 | |
| SCHEMBL3603276 | 0.79 | CHRM4 (0.52) | — | |
| SCHEMBL3963853 | 0.78 | ACE (0.46) | HTR2CHTR2BPARP1HTR2AMAPK1 | |
| SCHEMBL2100919 | 0.77 | BRD4 (0.50) | HTR2CHTR2BPARP1HTR2AMAPK1 | |
| SCHEMBL31184539 | 0.77 | BRD4 (0.50) | HTR2CHTR2BPARP1HTR2AMAPK1 | |
| SCHEMBL31184549 | 0.77 | BRD4 (0.50) | HTR2CHTR2BPARP1HTR2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842808-B2 | calcitonin gene-related peptide receptors antagonists such as 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid[2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide, used for treating headaches, pain, hot flashes or respiratory system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842808-B2 | calcitonin gene-related peptide receptors antagonists such as 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid[2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide, used for treating headaches, pain, hot flashes or respiratory system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7754732-B2 | Spirocyclic anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754732-B2 | Spirocyclic anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | VDAC1, HTR3B, FAAH | HTR2C 110/4885HTR2B 56/4885PARP1 2176/4885 |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | CALCRL, CALCR, CALCA | HTR2C 443/4885HTR2B 259/4885PARP1 2169/4885 |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | CALCRL, CALCR, CALCA | HTR2C 415/4885HTR2B 240/4885PARP1 1931/4885 |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BDKRB2, PTGIR, CALCRL | HTR2C 383/4885HTR2B 245/4885PARP1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.